DMTK(Delisted)
DermTech·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 1
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About DMTK
Dermtech, Inc.
A leading developer of non-invasive gene expression tests for skin health and cancer diagnosis
12340 El Camino Real, San Diego, CA 92130
--
DermTech, Inc., which was incorporated on July 31, 2015, completed its merger in Delaware, USA on August 29, 2019. The company is a molecular diagnostic company that develops and markets novel non-invasive genomics tests to help diagnose and manage skin cancer, inflammatory skin diseases and skin diseases associated with aging. The company's technology enhances the detection of early melanomas by non-invasive detection of genomic markers associated with melanomas, thereby identifying higher-risk lesions at an early stage, thereby excluding melanomas with more than 99% negative predictive values.
Company Financials
EPS
DMTK has released its 2024 Q1 earnings. EPS was reported at -0.58, versus the expected -0.57, missing expectations. The chart below visualizes how DMTK has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
DMTK has released its 2024 Q1 earnings report, with revenue of 3.85M, reflecting a YoY change of 10.58%, and net profit of -20.01M, showing a YoY change of 36.01%. The Sankey diagram below clearly presents DMTK's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
